PHARMAC funds tocilizumab to treat cases of COVID-19

16 September 2021 - PHARMAC is widening funded access to tocilizumab, an immunosuppressive drug used mainly to treat arthritis, to treat ...

Read more →

PHARMAC funds new treatment for rheumatoid arthritis to support people impacted by tocilizumab stock shortage

16 September 2021 - PHARMAC has funded upadacitinib tablets as an alternative treatment for New Zealanders with severe rheumatoid arthritis, ...

Read more →

NHS lung cancer patients in England get early access to ‘breakthrough’ cancer drug

10 September 2021 - The MHRA has approved a first-of-its-kind cancer drug – capable of targeting a gene mutation that ...

Read more →

Insurance benefits for Pfizer’s heart drug Vyndamax uncertain

9 September 2021 - Pfizer’s Vyndamax (tafamidis), a treatment for transthyretin amyloid cardiomyopathy, got in the European Society of Cardiology’s ...

Read more →

Consumers to have more say on medicine access issues

7 September 2021 - Consumer involvement in Australia’s medicines choices has been further strengthened under a new strategic agreement Medicines ...

Read more →

MSD Australia endorses new medicines strategic agreement

8 September 2021 - MSD Australia has today welcomed the signing of a new Medicines Strategic Agreement between Medicines Australia ...

Read more →

Withdrawals from pharmaceutical benefits on 1 October 2021

8 September 2021 - Suboxone is among the medicines that will be withdrawn from the drug benefits at the companies' ...

Read more →

Landmark new medicines agreements to bring significant benefits for Australian patients

7 September 2021 - Australians will have more affordable, improved and guaranteed access to medicines under landmark long-term strategic agreements between ...

Read more →

New strategic agreements with the medicines industry

7 September 2021 - The Australian Government has entered into new strategic agreements with Medicines Australia and the Generic and ...

Read more →

Leap forward for patients accessing medicines

7 September 2021 - Medicines Australia has secured a 5 year strategic agreement with the Federal Government, centered on earlier ...

Read more →

New treatment option for schizophrenia Reagila listed on PBS

6 September 2021 - Adults living with schizophrenia will have access to a new treatment option with Reagila (cariprazine), reimbursed ...

Read more →

Patients in the Netherlands wait 1.5 years for access to new medicines

2 September 2021 - Patients in the Netherlands have to wait an average of 510 days for access to a new ...

Read more →

CAR-T therapy Kymriah fails to get insurance benefits

2 September 2021 - The first CAR-T therapy, Kymriah (ingredient: tisagenlecleucel), failed to pass the review of a panel at ...

Read more →

Price relief as epilepsy drug PBS listed

1 September 2021 - Australian epilepsy sufferers will now be reimbursed for a drug that reduces uncontrolled seizures, as a ...

Read more →

Schedule of Pharmaceutical Benefits - 1 September 2021 update

1 September 2021 - The September 2021 issue of the Schedule of Pharmaceutical Benefits is out and now in effect. ...

Read more →